BR9807895A - Uso do bloqueador do canal de sódio na fabricação de um medicamento para a prevenção da degeneração do nervo óptico associada ao glaucoma. - Google Patents

Uso do bloqueador do canal de sódio na fabricação de um medicamento para a prevenção da degeneração do nervo óptico associada ao glaucoma.

Info

Publication number
BR9807895A
BR9807895A BR9807895-0A BR9807895A BR9807895A BR 9807895 A BR9807895 A BR 9807895A BR 9807895 A BR9807895 A BR 9807895A BR 9807895 A BR9807895 A BR 9807895A
Authority
BR
Brazil
Prior art keywords
retinal ganglion
glaucoma
cells
inactivable
ganglion cells
Prior art date
Application number
BR9807895-0A
Other languages
English (en)
Inventor
Joseph S Adorante
Original Assignee
Allergan Sales Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Sales Inc filed Critical Allergan Sales Inc
Publication of BR9807895A publication Critical patent/BR9807895A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Patente de Invenção: <B>''USO DO BLOQUEADOR DO CANAL DE SóDIO NA FABRICAçãO DE UM MEDICAMENTO PARA A PREVENçãO DA DEGENERAçãO DO NERVO óPTICO ASSOCIADA AO GLAUCOMA''<D>. Método e composição para alterar uma seq³ência plausível de eventos patológicos em células do gânglio retiniano associados ao glaucoma, a seq³ência incluindo a despolarização da membrana, o influxo de quantidades milimolares de Na^ +^ através de canais de Na^ +^ não-inativáveis, e a elevação letal de Ca^ 2+^ celular devido à reversão do trocador de Na^ +^. O método inclui o bloqueio, por administração de uma composição selecionada, dos canais de Na^ +^ não-inativáveis associados a células do gânglio retiniano, para limitar a troca de Na^ +^/Ca^ 2+^ nas células do gânglio retiniano e evitar a elevação do nível de Ca^ 2+^ nas células do gânglio retiniano a um nível letal. Isso resulta em um método para prevenir a morte de células do gânglio retiniano, associada ao glaucoma, pela administração ao nervo óptico de um mamífero de um composto que bloqueie os canais de íon sódio não-inativáveis do nervo óptico. Alternativamente, a dita invenção refere-se a um método para prevenir a morte de células do gânglio retiniano óptico em um ser humano pela administração às células do gânglio retiniano do dito ser humano de um composto que bloqueie o canal de íon sódio não-inativável das células do gânglio retiniano.
BR9807895-0A 1997-03-27 1998-03-26 Uso do bloqueador do canal de sódio na fabricação de um medicamento para a prevenção da degeneração do nervo óptico associada ao glaucoma. BR9807895A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/827,194 US5922746A (en) 1997-03-27 1997-03-27 Inhibition of noninactivating Na channels of mammalian optic nerve as a means of preventing optic nerve degeneration associated with glaucoma
PCT/US1998/005941 WO1998043612A1 (en) 1997-03-27 1998-03-26 Use of sodium channel blocker in the manufacture of a medicament for preventing optic nerve degeneration associated with glaucoma

Publications (1)

Publication Number Publication Date
BR9807895A true BR9807895A (pt) 2000-02-22

Family

ID=25248552

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9807895-0A BR9807895A (pt) 1997-03-27 1998-03-26 Uso do bloqueador do canal de sódio na fabricação de um medicamento para a prevenção da degeneração do nervo óptico associada ao glaucoma.

Country Status (13)

Country Link
US (6) US5922746A (pt)
EP (1) EP0973500A1 (pt)
JP (1) JP2001521500A (pt)
KR (1) KR100610997B1 (pt)
CN (1) CN1251520A (pt)
AU (1) AU734432B2 (pt)
BR (1) BR9807895A (pt)
CA (1) CA2284940A1 (pt)
HU (1) HUP0001268A2 (pt)
IL (1) IL132001A (pt)
NO (1) NO994674L (pt)
NZ (1) NZ337604A (pt)
WO (1) WO1998043612A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001041756A2 (en) * 1999-12-02 2001-06-14 University Of South Florida Method and composition for treatment of ischemic neuronal reperfusion injury
GB0002666D0 (en) 2000-02-04 2000-03-29 Univ London Blockade of voltage dependent sodium channels
US20060013814A1 (en) * 2000-08-29 2006-01-19 Davies Collison Cave Methods for preventing pressure-induced apoptotic neural-cell death
AU2002239329B2 (en) * 2000-11-22 2006-08-10 Allergan, Inc. A high-throughput screen for identifying channel blockers that selectively distinguish transient from persistent sodium channels
US6479458B1 (en) * 2001-11-08 2002-11-12 Allergan, Inc. Targeting the reverse mode of the Na+/Ca2+ exchanger for the treatment of optic neuropathy associated with glaucoma and ischemic optic neuropathy
US7361478B2 (en) * 2001-11-20 2008-04-22 Allergan, Inc. High-throughput screen for identifying selective persistent sodium channels channel blockers
US20040058313A1 (en) * 2002-04-24 2004-03-25 Abreu Marcio Marc Compositions, targets, methods and devices for the therapy of ocular and periocular disorders
US20040220187A1 (en) * 2003-04-22 2004-11-04 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a sodium ion channel blocker for the treatment of pain, inflammation or inflammation mediated disorders
US7125908B2 (en) * 2003-08-29 2006-10-24 Allergan, Inc. Treating pain using selective antagonists of persistent sodium current
CA2537088A1 (en) * 2003-08-29 2005-03-10 Allergan, Inc. Using selective antagonists of persistent sodium current to treat neurological disorders and pain
US7060723B2 (en) 2003-08-29 2006-06-13 Allergan, Inc. Treating neurological disorders using selective antagonists of persistent sodium current
WO2007022568A1 (en) 2005-08-25 2007-03-01 Steven Michael Weiss Reducing myocardial damage and the incidence of arrhythmia arising from loss, reduction or interruption in coronary blood flow
WO2016100209A1 (en) * 2014-12-15 2016-06-23 The Children's Medical Center Corporation Non-toxic topical anesthetic ophthalmic compositions
US10791651B2 (en) 2016-05-31 2020-09-29 Carbice Corporation Carbon nanotube-based thermal interface materials and methods of making and using thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06172176A (ja) * 1992-12-03 1994-06-21 Rohto Pharmaceut Co Ltd アジマリンを必須成分とする眼圧降下剤
FR2702148B1 (fr) * 1993-03-05 1995-04-07 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement du neuro-sida.
GB9326010D0 (en) * 1993-12-21 1994-02-23 Sandoz Ltd Improvements in or relating to organic compounds
FR2714828B1 (fr) * 1994-01-12 1996-02-02 Rhone Poulenc Rorer Sa Application du riluzole dans le traitement des maladies mitochondriales.
EP0757555A4 (en) * 1994-01-14 1999-04-07 Lee Shahinian Jr METHOD FOR LONG-LASTING AND EXTENDED CORNEAL ANALGESIA

Also Published As

Publication number Publication date
KR100610997B1 (ko) 2006-08-10
US6426358B1 (en) 2002-07-30
US20020040042A1 (en) 2002-04-04
US6420402B2 (en) 2002-07-16
AU734432B2 (en) 2001-06-14
CA2284940A1 (en) 1998-10-08
IL132001A0 (en) 2001-03-19
US6326389B1 (en) 2001-12-04
US20020183368A1 (en) 2002-12-05
IL132001A (en) 2005-07-25
HUP0001268A2 (hu) 2000-12-28
JP2001521500A (ja) 2001-11-06
KR20000076334A (ko) 2000-12-26
NZ337604A (en) 2001-03-30
WO1998043612A1 (en) 1998-10-08
EP0973500A1 (en) 2000-01-26
US20020013353A1 (en) 2002-01-31
US20020137777A1 (en) 2002-09-26
NO994674L (no) 1999-11-25
CN1251520A (zh) 2000-04-26
AU6776298A (en) 1998-10-22
NO994674D0 (no) 1999-09-24
US5922746A (en) 1999-07-13

Similar Documents

Publication Publication Date Title
BR9807895A (pt) Uso do bloqueador do canal de sódio na fabricação de um medicamento para a prevenção da degeneração do nervo óptico associada ao glaucoma.
Mueller et al. Inhibition of neuronally induced tyrosine hydroxylase by nicotinic receptor blockade
Edwards et al. Apoptosis in perinatal hypoxic‐ischaemic cerebral damage
CL2010000606A1 (es) Uso de derivados de eritropoyetina en la preparacion de un medicamento util para proteger, mantener, mejorar o recuperar la viabilidad de celulas que responden a eritropoyetina en condiciones anomalas que afectan las celulas, tejidos u organos asociados; derivados de eritropoyetinas y composicion que las comprende (divisional de la solicitud 3188-2001).
DE60022333D1 (de) Natrium kanalblocker zusammensetzungen und deren verwendung
AR008387A1 (es) Nuevas 5-fenoxialquil-tiazolidin-2,4-dionas, procedimientos para obtenerlas, nuevos compuestos intermedios de estos procedimientos ycomposiciones farmaceuticas que contienen las nuevas 5-fenoxialquil-tiazolidin- 2,4-dionas
DK0950057T3 (da) 3-pyridylenantiomerer og deres anvendelse som analgetika
BRPI0415179A (pt) derivados de amida como ligandos de canal de ìon e composições farmacêuticas e métodos de empregar as mesmas
Langston et al. Antiviral medication and corneal wound healing
WO1998043612B1 (en) Use of sodium channel blocker in the manufacture of a medicament for preventing optic nerve degeneration associated with glaucoma
FI950439A0 (fi) 3&#39;-atsido-3&#39;-deoksitymidiinin kontrolloidusti vapauttavat farmaseuttiset valmisteet ja käyttömenetelmät
Remuzzi et al. Regression of diabetic complications by islet transplantation in the rat
Anniko et al. Comparative ototoxicities of gentamicin and netilmicin in three model systems
Hyndiuk et al. Newer compounds in therapy of herpes simplex keratitis
BR9912816A (pt) Composição terapêutica à base de flavonóides, tencionada para uso no tratamento de tumores por agentes citotóxicos
Weitzner Plexiform neurofibroma of major salivary glands in children
DE69803670T2 (de) Tiagabinhaltige arzneizubereitungen mit gesteuerter wirkstoffverabreichung
ES2108642B1 (es) Composiciones de tungsteno (vi) para el tratamiento oral de la diabetes mellitus.
Takigawa et al. Early changes in human epidermis following thermal burn: an electron microscopic study
Shiota Clinical evaluation of acyclovir in the treatment of ulcerative herpetic keratitis
Silvestri Ichthyosiform dermatosis and deafness
Sullivan et al. Temperature dependence of muscle function in malignant hyperpyrexia-susceptible swine
F Ahmed The effect of rifampicin and isoniazid on liver and lung tissues in rats
Kimura et al. Histopathological study of the cochlea with altered perilymph metabolism
Collins et al. 8‐Methoxypsoralen bath PUVA clears psoriasis after failure of oral PUVA

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Free format text: ALLERGAN, INC. (US)

B25K Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: republication

Free format text: REFERENTE A RPI 1787 DE 20050405 - CODIGO 25.1 - ITEM 71 - QUANTO AO NOME DO DEPOSITANTE.

B25A Requested transfer of rights approved

Free format text: ALLERGAN, INC. (US)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIMENTO DO PRESENTE PEDIDO COM BASE NOS ART. 10 ( VIII ), 8O E 13 DA LPI 9.279, DE 14 DE MAIO DE 1996